In addition to weighing in on the ongoing 340B contract pharmacy standoff (see related story), the U.S. House Appropriations Committee has entered the thicket of the highly controversial topics of 340B patient definition and provider eligibility.
In its report accompanying the funding bill that includes the U.S Health Resources and Services Administration (HRSA), the committee directs:
In addition to weighing in on the ongoing 340B contract pharmacy standoff (see related story), the U.S. House Appropriations Committee has entered the thicket of the highly controversial topics of 340B patient definition and provider eligibility.
In its report accompanying the funding bill that includes the U.S Health Resources and Services Administration (HRSA), the committee directs:
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
